---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-25-011926"
form_type: "8-K"
ticker: "GOVX"
cik: "0000832489"
company_name: "GeoVax Labs, Inc."
filed_at: "2025-04-14T23:59:59+00:00"
generated_at: "2026-05-23T15:52:36.966276+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# BARDA terminates GeoVax's Phase 2b COVID-19 vaccine contract for convenience

## Summary
- On April 11, 2025, GeoVax received stop-work notice from ATI/BARDA for Project Agreement RRPV-24-04-NGVx-006.
- Contract covered Phase 2b clinical trial of GEO-CM04S1 COVID-19 vaccine; terminated for convenience to the government.
- No financial details of termination or potential wind-down costs were disclosed in the filing.
- GeoVax common stock (GOVX) and warrants (GOVXW) trade on Nasdaq Capital Market.

## SEC filing metadata
- accession: 0001437749-25-011926
- form_type: 8-K
- ticker: GOVX
- cik: 0000832489
- company_name: GeoVax Labs, Inc.
- filed_at: 2025-04-14T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/832489/000143774925011926/0001437749-25-011926-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/832489/000143774925011926/govx20250414_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-25-011926
- JSON: https://secwatch.observer/filing/0001437749-25-011926.json
- Plain text: https://secwatch.observer/filing/0001437749-25-011926.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.